**Synthesis and Anticandidal Activity of New 6-Chloroimidazo[1,2-*a*] pyridine Derivatives**

ABSTRACT

|  |
| --- |
| **Aims:** The general objective assigned to this work was to contribute to the pharmacochemical development of new antifungal drugs derived from 6-Chloroimidazo[1,2-*a*]pyridine. This preliminary study was conducted on *Candida parapsilosis*, which is an increasingly difficult organism to treat.**Methodology:** The imidazo[1,2-*a*]pyridinylacrylonitriles designed by juxtaposition of bioactive entities were synthesized in three steps. Firstly, this involves the synthesis of the imidazopyridine core via cyclocondensation. Then, its functionalization at position 2 with an acetonitrile group, and finally condensation of the resulting intermediate with various aromatic aldehydes**Results:** A total of ten derivatives of (6-chloroimidazo[1,2-*a*]pyridin-2-yl)-phenylacrylonitrile were obtained, with yields ranging from 63% to 92%. The biological evaluation focused on the antifungal activity of these compounds against a clinical strain of *Candida parapsilosis*, with minimum inhibitory concentrations (MIC) ranging from 19.36 µM to 89.38 µM. Structure–activity relationship (SAR) analysis revealed that the nature and position of the substituent on the aryl ring significantly modulate antifungal efficacy. These findings highlight the pharmacochemical relevance of electron-withdrawing or polarizable substituents in enhancing antifungal activity.**Conclusion:** Due to their innovative profile combining a functional chain and a bioactive pharmacophore, these novel imidazo[1,2-a]pyridine hybrids appear as promising candidates for the development of potent antifungal agents, particularly against Candida species. |

*Keywords:* Imidazo[1,2-*a*]pyridine, Acrylonitrile, anticandidosis, antiinfective

1. INTRODUCTION

Opportunistic fungal infections, particularly those caused by *Candida* species, represent a major public health problem, especially in immunocompromised, transplanted, or HIV patients [1]. Fungal diseases affect more than one billion people annually and cause approximately 1.5 million deaths worldwide [2]. Among them, invasive *Candida* spp. infections are of particular concern because they are associated with severe morbidity and represent nearly 30% of global mortality related to mycoses [3]. Among these species, *Candida albicans, Candida tropicalis* and *Candida glabrata* are responsible for severe systemic candidiasis [4]. Apart from these *Candida* species, other non-albicans species, such as *Candida parapsilosis*, seem to be gaining importance in the etiology of candidemia [5]. Indeed, according to A. Paugam et al., *C. parapsilosis* candidemia is associated with two main factors: broad-spectrum antibiotic therapy and prior treatment with caspofungin [6]. They reported that the emergence of *C. parapsilosis* candidemia appears to coincide with the introduction of caspofungin, suggesting a possible association with its level of use in intensive care [6]. *C. parapsilosis* infections constitute a growing threat to public health. Therefore, the search for new agents active against *Candida parapsilosis* is considered urgent by the WHO because this germ is on the list of priority pathogens [7].

Although several antifungals are available on the market, such as polyenes, echinocandins and azoles, the emergence of multiple resistances compromises their efficacy and justifies the urgent search for new classes of active molecules [8-10]. In this perspective, medicinal chemistry research has focused on the design of hybrid structures combining pharmacophore motifs known for their anti-infectious activity [11]. It is in this context that our team has focused on the imidazo[1,2-*a*]pyridine heterocycle, a diazole bioisostere of benzimidazole, known for its wide range of biological activities, including antifungal, antiparasitic and anticancer properties [12-14].

On the other hand, the acrylonitrile group, by its α,β-unsaturated electrophilic nature, is a Michael acceptor capable of interacting covalently with the thiol residues of certain target proteins [15 - 18]. This chemical fragment is already present in many anti-infective drugs, such as rilpivirine (antiretroviral) and neratinib (anticancer), and has demonstrated a remarkable ability to potentiate the biological activity of the heterocycles to which it is grafted [19, 20]. In a previous study, we designed new imidazopyridinyl-acrylonitrile derivatives that could exhibit strong antifungal activity, particularly against resistant clinical strains of *Candida* [13]. Preliminary data revealed promising profiles, with some compounds surpassing fluconazole, the reference molecule, in terms of activity against *C. tropicalis, C. glabrata* and *C. albicans* [13]. The 3-chlorinated derivative proved to be the most effective, regardless of the Candida species considered. Structure-activity relationship (SAR) analysis also identified key groups (Cl) that significantly enhance antifungal activity [13]. Furthermore, chlorine has demonstrated its ability to boost the antifungal activities of many currently marketed drugs, particularly those in the azole antifungal class (ketoconazole, econazole, isoconazole, miconazole, etc.). Therefore, It was opportune to study its impact on a series of imidazopyridine-based derivatives, which, like the imidazole nucleus, is a diazaheteroaryl. In this study, we developed 6-chloro derivatives of imidazo[1,2*-a*]pyridinylphenylacrylonitriles for anticandidal purposes.

To this end, we undertook to evaluate the antifungal activity of these synthetic compounds against *Candida parapsislosis*. The results of such a study could pave the way for the development of new anticandidal molecules capable of circumventing growing fungal drug resistance and strengthening the current therapeutic arsenal.

2. methodology

**2.1 General considerations**

The progress of the reactions was monitored by thin layer chromatography (TLC) on aluminum plates coated using Merk® silica gel 60F254 plates. The development was done with UV light (λ = 254 nm) with a mixture of ethyl acetate and hexane (70:30) as eluent. NMR experiments were performed at 300.13 mHz (1H) and 75. 46 mHz (13C) on a Bruker-Avance 300 MHz spectrometer. Chemical shifts (δ) are measured in parts per million (ppm) using tetramethylsilane as the internal reference solvent.

At the residual signal of chloroform (7.26 ppm for proton NMR, 77.16 ppm for carbon NMR) for spectra carried out in deuterated chloroform (CDCl3), at the residual signal of dimethyl sulfoxide (2.50 ppm for proton NMR and 39.52 ppm in carbon NMR) for spectra carried out in dimethyl sulfoxide hexadeuterated (DMSO-d6).

The coupling constants (*J*) are expressed in Hertz (Hz) and the multiplicity of the signals is described as follows: singlet (s), wide singlet (sl), doublet (d), doublet of doublet (dd), split doublet of doublet (ddd), triplet of doublet (td), quadruplet (q) and multiplet (m). Melting points of the compounds were determined on a Köfler bench and are uncorrected.

**2.2 Synthesis of 6-chloro-2-(chloromethyl)imidazo[1,2-*a*]pyridine**

The imidazo[1,2-*a*]pyridinylacrylonitriles, were synthesized in 3 steps. This involves first of all the construction of the imidazopyridine core by cyclocondensation, then its functionalization in position 2 by the acetonitrile group and finally the condensation of this intermediate with an aromatic aldehyde. Formation of the imidazo[1,2-*a*]pyridine ring resulted in the formation of 6-chloro-2-(chloromethyl)imidazo[1,2-*a*]pyridine **1.** Indeed, this synthesis which follows the classical scheme was carried out by condensation of 5-chloro-2-aminopyridine **a** and 1,2-dichloroacetone **b.** On the other hand, various approaches in the literature have been addressed, using solvents such as DMF [21], ethyl acetate [22], ethanol [23]and methanol [24].For our study, we opted for acetonitrile as the reaction medium (**Figure 1)**.



Fig 1. Synthesis of proposed imidazo[1,2-*a*]pyridinehybrid derivatives

Once the core is formed, the next step is to synthesize the acetonitrile intermediate, 2-(imidazo[1,2- *a*]pyridin-2-yl)acetonitrile **2**, which would promote condensation.

* **Method for synthesis of 2-chloromethyl imidazo[1, 2-*a*]pyridine**

To a solution of 2.35 g (24.9 mmol, 1 eq) of 2-amino-4-chloropyridine in 25 ml of acetonitrile, are added and 3.2 g (25.2 mmol, 1.01 eq) of 1,3-dichloroacetone. The mixture is left stirring at room temperature for 12 hours. The precipitate formed is isolated by vacuum filtration, washed with 2 times 15 ml of acetonitrile, drained and then dried at room temperature. The residue is then dissolved in 60 ml of water and the solution is neutralized with a saturated solution of sodium hydrogen carbonate (NaHCO3). The impurities are extracted from the mixture with 2 times 15 ml of ethyl acetate, then the aqueous phase is stored in the refrigerator (5°C) and the product precipitates after one hour. After vacuum filtration, the product is isolated as a white flaky solid, with a yield of 49.28%.

**2.3****Synthesis of 2-(6-chloroimidazo[1,2-a]pyridin-2-yl)acetonitrile**

2-(6-chloroimidazo[1,2-*a*]pyridin-2-yl)acetonitrile **2**​was prepared by the cyanation of 6-chloro-2-(chloromethyl)imidazo[1,2-*a*]pyridine **1** using potassium cyanide. The reaction takes place in dimethyl sulfoxide (DMSO) at room temperature (**Figure 1**).

* **Method for synthesis of 2-(6-chloroimidazo[1,2-a]pyridin-2-yl)acetonitrile**

A mixture of 2-chloromethyl imidazo[1,2-*a*]pyridine (1g; 6 mmol; 1eq) and potassium cyanide (0.43; 6.6 mmol; 1.1 eq) was stirred for 12 h at room temperature in a 100 ml flask containing 10 ml of DMSO. The brown liquid was extracted with dichloromethane (2 x 50 ml), then washed with 2 times 50 ml of water. The organic phase was dried over magnesium sulfate, filtered and concentrated under vacuum. The brown paste formed crystallized after 30 minutes at room temperature, with a yield of 87.23%.

**2.4 Synthesis of (Z)-2-(6-chloroimidazo[1,2-a]pyridin-2-yl)-3-phenylacrylonitrile derivatives**

This is the reaction of an activated methylene with aromatic aldehydes. The method used consists of treating compound **2** and benzaldehyde substituted or notin a hot medium, In presence of piperidine. We obtained phenylacrylonitrile derivatives with imidazo[1,2-*a*]pyridine support compounds **3a-3j** (**Figure 1**) .

* **General method of synthesis of imidazo[1,2-*a*]pyridine phenylacrylonitrile**

To a solution of 0.5 g (3.18 mmol; 1 eq) of 2-(imidazo[1,2-*a*]pyridin-2-yl)acetonitrile in 8 ml of anhydrous ethanol, 5 drops of piperidine and 3.2 g (3.5 mmol; 1.1 eq) of benzaldehyde are added. The mixture is refluxed for 12 h. The precipitate formed is isolated by vacuum filtration, washed with 10 ml of cold methanol, drained and then dried at room temperature. The product which is the unsubstituted derivative **(3a)** is isolated in the form of a yellow solid, with a yield of 70%.

The other derivatives with different substituents (4-OH; 4-OCH3; 4-CH3; 4-F; 4-NO2; 4-N(CH3)2; 2-Cl; 2,4-Cl; 4-Cl) were obtained using the same method.

**2.5 Biology**

**2.5.1 Microbiological Material**

To evaluate the antifungal activity of the products, we used a clinical strain of *Candida parapsilosis* (strain 418068) from the parasitology laboratory of the Angré University Hospital, Abidjan, Côte d'Ivoire.

**2.5.2 Determination of Minimum Inhibitory Concentrations (MICs) by Microplate Dilution**

The antifungal activity of the compounds was assessed using the microplate dilution method, aiming to determine the minimum inhibitory concentrations (MICs) against Candida strains. This technique involves exposing a fungal inoculum to increasing concentrations of test substances in 96-well plates.

The *Candida* inoculum was prepared using the same conditions as those described for the bioautography assay. Stock solutions of imidazo[1,2-*a*]pyridinylphenylacrylonitrile compounds were prepared at 1 mg/mL in dimethyl sulfoxide (DMSO), then diluted in BTS broth to achieve an initial concentration of 188 µg/mL.

A volume of 188 µL of this solution was distributed into the wells of the first column of the microplate. The remaining wells received 58 µL of BTS broth, followed by a series of two-fold dilutions by transferring 58 µL from one well to the next.

Next, 58 µL of fungal inoculum was added to each well (except the last well, which was used as a sterility control), and the plates were incubated at 30°C for 48 hours.

To detect fungal growth, 48 µL of a 2.5 mg/mL aqueous solution of methylthiazolyltetrazolium chloride (MTT) was added to each well, followed by a 30-minute incubation at room temperature. The color change of the medium, from yellow to purple, indicates cell viability via mitochondrial dehydrogenase activity.

The MIC was defined as the lowest concentration of the compound for which no color change (yellow → purple) is observed, indicating complete inhibition of fungal growth.

3. results and discussion

**3.1 Results**

**3.1.1 Chemistry**

We obtained 10 compounds derived from 6-chloroimidazo[1,2-*a*]pyridin-2-yl)-phenylacrylonitrile (**3a** to **3j**) with yields varying between 63 and 92%. These compounds are presented as powder of variable color. To confirm the identity of the ten synthesized (Z)-2-(6-chloroimidazo[1,2-*a*]pyridin-2-yl)-3-phenylacrylonitriles. The synthesized compounds were characterized by 1H and 13C NMR. Here NMR analysis data of synthesized imidazo[1,2-*a*]pyridine derivatives are presented:

(Z)-2-(6-Chloroimidazo[1,2-*a*]pyridin-2-yl)-3-phenylacrylonitrile (**3a**)

Yield – 70%. M. p. 181–185 °C. Yellow powder. RF = 0.87 cm (Mobile phase: Ethyl Acetate / Hexane, 60:40). 1H NMR (300 MHz, DMSO-d6), δ, ppm: 8.87 (1H, dd, *J* = 2.2, 0.9 Hz, ArH), 8.29 (1H, s, ArH), 8.23 (1H, s, ArH), 8.01–7.93 (2H, m, ArH), 7.69–7.60 (1H, m, ArH), 7.60–7.48 (3H, m, ArH), 7.41 (1H, dd, J = 9.6, 2.1 Hz, ArH). 13C NMR (75 MHz, DMSO-d6), δ, ppm: 144.08, 141.94, 141.37, 133.79, 131.32, 129.60, 127.87, 125.74, 119.97, 117.85, 112.48, 104.21.

(Z)-2-(6-Chloroimidazo[1,2-*a*]pyridin-2-yl)-3-(4-hydroxyphenyl)acrylonitrile (**3b**)

Yield – 63%. M. p. 155–157 °C. Yellow lumpy powder. RF = 0.80 cm (Mobile phase: Ethyl Acetate / Hexane, 70:30). 1H NMR (300 MHz, DMSO-d6), δ, ppm: 8.88–8.83 (1H, m, ArH), 8.23 (1H, s, ArH), 8.16 (1H, s, ArH), 8.02–7.95 (2H, m, ArH), 7.63 (1H, d, *J* = 9.6 Hz, ArH), 7.39 (1H, dd, *J* = 9.6, 2.1 Hz, ArH), 7.15–7.09 (2H, m, ArH). 13C NMR (75 MHz, DMSO-d6), δ, ppm: 161.8, 144.0, 141.8, 141.7, 131.7, 127.6, 126.4, 125.6, 119.8, 118.3, 117.7, 115.2, 111.8, 100.9.

(Z)-2-(6-Chloroimidazo[1,2-*a*]pyridin-2-yl)-3-(4-methoxyphenyl)acrylonitrile (**3c**)

Yield – 65%. M. p. 176–178 °C. Yellow crystalline powder. RF = 0.77 cm (Mobile phase: Ethyl Acetate / Hexane, 70:30). 1H NMR (300 MHz, CDCl3), δ, ppm: 8.16 (1H, d, *J* = 1.1 Hz, ArH), 8.11 (1H, s, ArH), 7.90 (2H, d, *J* = 8.6 Hz, ArH), 7.81 (1H, s, ArH), 7.55 (2H, dd, *J* = 15.1, 9.2 Hz, ArH), 6.95–6.89 (3H, m, ArH), 3.84 (2H, d, *J* = 8.2 Hz, OCH3).

13C NMR (75 MHz, CDCl3), δ, ppm: 131.15, 127.12, 126.40, 125.14, 119.80, 118.32, 117.70, 115.15, 111.78.

(Z)-2-(6-Chloroimidazo[1,2-*a*]pyridin-2-yl)-3-(p-tolyl)acrylonitrile (**3d**)

Yield – 67%. M. p. 152–154 °C. Yellow crystalline powder. RF = 0.76 cm (Mobile phase: Ethyl Acetate / Hexane, 70:30). 1H NMR (300 MHz, CDCl3), δ, ppm: 8.13–8.10 (1H, m, ArH), 7.93 (1H, dd, *J* = 1.9, 0.8 Hz, ArH), 7.84–7.77 (1H, m, ArH), 7.54 (1H, d, *J* = 9.6 Hz, ArH), 7.34 (1H, d, *J* = 0.4 Hz, ArH), 7.29 (1H, s, ArH), 7.11 (1H, dd, *J* = 9.6, 2.0 Hz, ArH), 6.97 (2H, d, *J* = 8.0 Hz, ArH), 5.77 (1H, s, ArH), 2.20 (3H, s, CH3). 13C NMR (75 MHz, CDCl3), δ, ppm: 142.9, 142.2, 138.3, 130.4, 129.9, 129.6, 129.1, 127.7, 126.7, 123.7, 121.2, 118.4, 117.7, 112.2, 111.2, 54.7, 44.5.

(Z)-2-(6-Chloroimidazo[1,2-*a*]pyridin-2-yl)-3-(4-fluorophenyl)acrylonitrile (**3e**)

Yield – 84%. M. p. 196–200 °C. Fine yellow powder. RF = 0.85 cm (Mobile phase: Ethyl Acetate / Hexane, 70:30). 1H NMR (300 MHz, CDCl3), δ, ppm: 8.88–8.84 (1H, m, ArH), 8.40 (1H, s, ArH), 8.35 (1H, s, ArH), 8.13–8.07 (1H, m, ArH), 7.71 (1H, d, J = 9.7 Hz, ArH), 7.68–7.64 (1H, m, ArH), 7.58–7.51 (2H, m, ArH), 7.44 (1H, dd, *J* = 9.6, 2.2 Hz, ArH). 13C NMR (75 MHz, CDCl3), δ, ppm: 144.5, 141.9, 138.7, 135.3, 132.1, 131.6, 130.2, 129.3, 127.9, 127.3, 123.9, 121.3, 118.2, 116.9, 111.84, 107.1.

(Z)-2-(6-Chloroimidazo[1,2-*a*]pyridin-2-yl)-3-(4-nitrophenyl)acrylonitrile (**3f**)

Yield – 90%. M. p. 204–208 °C. Fine green powder. RF = 0.60 cm (Mobile phase: Ethyl Acetate / Hexane, 70:30). 1H NMR (300 MHz, CDCl3), δ, ppm: 8.86 (1H, dd, *J* = 2.2, 0.9 Hz, ArH), 8.34 (2H, d, *J* = 10.7 Hz, ArH), 8.11 (1H, d, *J* = 8.4 Hz, ArH), 7.87 (1H, d, *J* = 2.2 Hz, ArH), 7.74–7.63 (2H, m, ArH), 7.44 (1H, dd, *J* = 9.6, 2.1 Hz, ArH).

13C NMR (75 MHz, CDCl3), δ, ppm: 140.83, 139.49, 131.15, 124.39, 117.91, 112.22, 107.55.

(Z)-2-(6-Chloroimidazo[1,2-*a*]pyridin-2-yl)-3-(4-(dimethylamino)phenyl)acrylonitrile (**3g**)

Yield – 76%. M. p. 196–200 °C. Brown lumpy powder. RF = 0.84 cm (Mobile phase: Ethyl Acetate / Hexane, 70:30). 1H NMR (300 MHz, CDCl3), δ, ppm: 8.19 (2H, s, ArH), 7.91 (1H, s, ArH), 7.88 (1H, s, ArH), 7.85 (1H, s, ArH), 7.56 (1H, d, *J* = 9.6 Hz, ArH), 7.47–7.45 (1H, m, ArH), 7.44–7.41 (1H, m, ArH), 7.26 (1H, dd, *J* = 9.6, 1.9 Hz, ArH). 13C NMR (75 MHz, CDCl3), δ, ppm: 130.9, 129.5, 124.0, 117.6, 111.6.

(Z)-2-(6-Chloroimidazo[1,2-a]pyridin-2-yl)-3-(2-chlorophenyl)acrylonitrile (**3h**)

Yield – 69%. M. p. 214–218 °C. Beige lumpy powder. RF = 0.85 cm (Mobile phase: Ethyl Acetate / Hexane, 70:30). 1H NMR (300 MHz, DMSO-d6), δ, ppm: 8.88–8.84 (1H, m, ArH), 8.40 (1H, s, ArH), 8.35 (1H, s, ArH), 8.13–8.07 (1H, m, ArH), 7.71 (1H, d, *J* = 9.7 Hz, ArH), 7.68–7.64 (1H, m, ArH), 7.58–7.51 (2H, m, ArH), 7.44 (1H, dd, *J* = 9.6, 2.2 Hz, ArH). 13C NMR (75 MHz, DMSO-d6), δ, ppm: 144.53, 141.89, 138.70, 135.27, 132.11, 131.55, 130.16, 129.33, 127.87, 127.32, 123.89, 118.16, 116.96, 111.84, 107.01.

(Z)-2-(6-Chloroimidazo[1,2-*a*]pyridin-2-yl)-3-(2,4-dichlorophenyl)acrylonitrile (**3i**)

Yield – 92%. M. p. 203–207 °C. Beige crystalline powder. RF = 0.79 cm (Mobile phase: Ethyl Acetate / Hexane, 70:30). 1H NMR (300 MHz, DMSO-d6), δ, ppm: 8.86 (1H, dd, *J* = 2.2, 0.9 Hz, ArH), 8.34 (2H, d, *J* = 10.7 Hz, ArH), 8.11 (1H, d, *J* = 8.4 Hz, ArH), 7.87 (1H, d, *J* = 2.2 Hz, ArH), 7.74–7.63 (2H, m, ArH), 7.44 (1H, dd, *J* = 9.6, 2.1 Hz, ArH). 13C NMR (75 MHz, DMSO-d6), δ, ppm: 144.28, 140.44, 136.41, 136.14, 135.19, 131.09, 130.79, 130.08, 128.50, 128.28, 125.85, 120.19, 118.08, 116.78, 113.45, 108.52.

(Z)-2-(6-Chloroimidazo[1,2-*a*]pyridin-2-yl)-3-(4-chlorophenyl)acrylonitrile (**3j**)

Yield – 79%. M. p. 196–200 °C. Brown powder. RF = 0.84 cm (Mobile phase: Ethyl Acetate / Hexane, 70:30). 1H NMR (300 MHz, CDCl3), δ, ppm: 8.19 (2H, s, ArH), 7.91 (1H, s, ArH), 7.88 (1H, s, ArH), 7.85 (1H, s, ArH), 7.56 (1H, d, *J* = 9.6 Hz, ArH), 7.47–7.45 (1H, m, ArH), 7.44–7.41 (1H, m, ArH), 7.26 (1H, dd, *J* = 9.6, 1.9 Hz, ArH). 13C NMR (75 MHz, CDCl3), δ, ppm: 130.88, 129.50, 124.00, 117.59, 111.61.

The value of this coupling constant indicates that the imidazopyridinyl-acrylonitrile derivatives have a cis or (Z) configuration [21].

**3.1.2 Antifungal activity**

The antifungal activity of a series of imidazo[1,2-a]pyridinyl-arylacrylonitrile derivatives was evaluated in vitro against *Candida parapsilosis* by determining minimum inhibitory concentrations (MICs), expressed in µM. The compounds, differing in the nature of the substituent on the aromatic ring (Ar) of the arylacrylonitrile unit, exhibited significant variations in efficacy (Table 1).

**Table 1. *In vitro* antifungal activities of imidazo[1,2*-a*]pyridinyl-arylacrylonitriles against *Candida parapsilosis***

|  |  |  |
| --- | --- | --- |
| **Compounds** | Chemical Structures | MIC (µM) |
| **3a** |  | 89.38  |
| **3b** |  | 42.27 |
|  |  |  |
| **3c** |  | 40.36 |
| **3d** |  | 85.11 |
| **3e** |  | 41.99 |
| **3f** |  | 38.49 |
| **3g** |  | 19.36 |
| **3h** |  | 39.79 |
| **3i** |  | 35.86 |
| **3j** |  | 39.79 |
| Fluconazole |  | <2.55 |

**3.2 Discussion**

Following antifungal evaluations against *Candida parapsilosis*, all the molecules tested exhibited anticandidal activity ranging from 19.36 to 89.38 µM. Fluconazole, the reference substance, showed remarkable antifungal activity of less than 2.55 µM. Analysis of structure-activity relationship trends shows that:

* + 1. **Effect of the unsubstituted group**

The reference compound (**3a**, Ar = H) exhibited limited activity (MIC = 89.38 µM), serving as a comparative basis.

* + 1. **Effects of different substitutions and parameter modifications**
* Influence of halogens:

Halogenated substituents moderately enhanced activity. Monochlorinated derivatives in the ortho (**3h**, MIC = 39.79 µM) or para (**3j**) positions show similar efficacy (2.2 x greater than non-substituted derivative **3a**), while the disubstituted 2,4-Cl (**3i**, MIC = 35.86 µM) suggests an additive effect. Fluorine derivative (**3e**, MIC = 41.99 µM) is slightly less active.

* Role of electron donors:

Hydroxy (**3b**, MIC = 42.27 µM) and methoxy (**3c**, MIC = 40.36 µM) derivatives provide only marginal improvement, while methyl (**3d**, MIC = 85.11 µM) remains less effective, reflecting the importance of polarizability.

* Impact of electron acceptors:

Nitro (**3f**, MIC = 38.49 µM) confers activity comparable to 4-Cl (**3j**), highlighting the benefits of electron-withdrawing substituents.

* Contribution of tertiary amines:

The dimethylamino group (**3g**, MIC = 19.36 µM) is distinguished by increased efficacy (4.6 times higher than **3a**), likely due to better solubility, membrane penetration, and affinity for fungal targets.

* Structural modulation of the aryl ring drastically influences antifungal activity.

Polarizable groups like (N(CH₃)₂; **3g**) or electron-withdrawing substituents like halogens or NO₂, significantly improve efficacy, while neutral (CH₃) or weakly donating (OCH₃) groups prove to be of little use. These results highlight the potential of halogenated and amine derivatives for the development of antifungal agents targeting *C. parapsilosis*, although their activity remains lower than that of fluconazole (MIC < 2.55 µM) used as reference drug.

4. Conclusion

This work is part of the search for new antifungal molecules. This is a preliminary work of pharmacochemistry whose aim is to propose molecules with a new chemical profile, with strong anticandidosis potential capable of circumventing the phenomena of drug resistance observed with most antifungal drugs. To do this, we designed, following the pharmacochemical concepts of molecular hybridization, molecules with a chemical profile of the type (6-chloroimidazo[1,2-*a*]pyridinyl)-3-phenylacrylonitriles. The synthesis of the expected imidazopyridine derivatives was carried out by condensation in a basic medium of imidazopyridines acetonitrile and aldehyde derivatives following the knoevenagel method.

Structure-activity relationship studies have allowed us to establish certain hypotheses. Halogen substituents, particularly chlorine in ortho or di-substituted (2,4-Cl) positions, moderately improved antifungal activity compared to the unsubstituted parent compound. Electron-donating groups such as methoxy or hydroxyl had negligible impact, while methyl substitution (4-CH₃) led to poor activity. In contrast, electron-withdrawing groups like nitro (4-NO₂) and especially the strongly polarizable dimethylamino group (4-N(CH₃)₂) resulted in substantial activity enhancement, the latter exhibiting the best performance with a MIC of 19.36 µM. Given that this preliminary study confirmed the antifungal potential of 6-chlorinated imidazopyridinyl acrylonitrile derivatives, such an evaluation of antifungal activity merits extension to other fungal species such as *Candida albibans*, *Candida glabrata*, *Candida tropical*, and *Aspergylus sp*, which are also priority organisms according to the WHO.

Disclaimer (Artificial intelligence)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

References

1. Seagle, E. E., Williams, S. L., & Chiller, T. M. (2021). Recent trends in the epidemiology of fungal infections. Infectious Disease Clinics of North America, 35(2), 237–260.
2. Bongomin, F., Gago, S., Oladele, R. O., & Denning, D. W. (2017). Global and multi-national prevalence of fungal diseases—estimate precision. Journal of Fungi, 3(4), 57. https://doi.org/10.3390/jof3040057
3. Strollo, S., Lionakis, M. S., Adjemian, J., Steiner, C. A., & Prevots, D. R. (2016). Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002–2012. Emerging Infectious Diseases, 23(1), 7–13. https://doi.org/10.3201/eid2301.161198
4. Katsipoulaki, M., Stappers, M. H. T., Malavia-Jones, D., Brunke, S., Hube, B., & Gow, N. A. R. (2024). Candida albicans and Candida glabrata: global priority pathogens. Microbiology and Molecular Biology Reviews, 88(1), e00021-23. <https://doi.org/10.1128/mmbr.00021-23>
5. Won, E. J., Sung, H., & Kim, M. N. (2024). Clinical characteristics of candidemia due to Candida parapsilosis with serial episodes: Insights from 5-year data collection at a tertiary hospital in Korea. Journal of Fungi (Basel), 10(9), 624. https://doi.org/10.3390/jof10090624
6. Paugam, A., Baixench, M.-T., Taieb, F., Champagnac, C., & Dupouy-Camet, J. (2011). Émergence de candidémies à Candida parapsilosis à l’hôpital Cochin. Caractérisation des isolats et recherche de facteurs de risque. Pathologie Biologie, 59(1), 44–47. <https://doi.org/10.1016/j.patbio.2010.08.009>
7. Asogan, M., Kim, H. Y., Kidd, S., Alastruey-Izquierdo, A., Govender, N. P., Dao, A., et al. (2024). Candida parapsilosis: A systematic review to inform the World Health Organization fungal priority pathogens list. Medical Mycology, 62(6), myad131. https://doi.org/10.1093/mmy/myad131
8. Boan, P., & Gardam, D. (2019). Epidemiology and antifungal susceptibility patterns of candidemia from a tertiary centre in Western Australia. Journal of Chemotherapy, 31(3), 137–140.
9. Asadzadeh, M., Ahmad, S., Al-Sweih, N., & Khan, Z. (2017). Epidemiology and molecular basis of resistance to fluconazole among clinical Candida parapsilosis isolates in Kuwait. Microbial Drug Resistance, 23(7), 966–972.
10. Ben-Ami, R., & Kontoyiannis, D. P. (2021). Resistance to antifungal drugs. Infectious Disease Clinics of North America, 35(2), 279–311. https://doi.org/10.1016/j.idc.2021.03.003
11. Viegas-Junior, C., Danuello, A., da Silva Bolzani, V., Barreiro, E. J., & Fraga, C. A. (2007). Molecular hybridization: A useful tool in the design of new drug prototypes. Current Medicinal Chemistry, 14(17), 1829–1852. https://doi.org/10.2174/092986707781058805
12. N’Guessan, J. P. D. U., Delaye, P. O., Pénichon, M., Charvet, C. L., Neveu, C., Ouattara, M., et al. (2017). Discovery of imidazo[1,2-a]pyridine-based anthelmintic targeting cholinergic receptors of Haemonchus contortus. Bioorganic & Medicinal Chemistry, 25(24), 6695–6706. https://doi.org/10.1016/j.bmc.2017.10.042
13. N’Guessan, D. U. J.-P., Coulibaly, S., Kassi, F. K., Delaye, P.-O., Pénichon, M., Enguehard-Gueiffier, C., et al. (2021). Synthesis and SAR of imidazo[1,2-a]pyridinylphenylacrylonitrile derivatives as potent anticandidiasis agents. Journal of Medicinal Chemistry and Sciences, 4(6), 554–563. https://doi.org/10.1021/acs.jmedchem.1c00544
14. Peytam, F., Emamgholipour, Z., Mousavi, A., Moradi, M., Foroumadi, R., Firoozpour, L., et al. (2023). Imidazopyridine-based kinase inhibitors as potential anticancer agents: A review. Bioorganic Chemistry, 140, 106831. <https://doi.org/10.1016/j.bioorg.2023.106831>
15. Fleming, F. F., Yao, L., Ravikumar, P. C., Funk, L., & Shook, B. C. (2010). Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. Journal of Medicinal Chemistry, 53(22), 7902–7917. https://doi.org/10.1021/jm100762r
16. Krishnan, S., Miller, R. M., Tian, B., Mullins, R. D., Jacobson, M. P., & Taunton, J. (2014). Design of reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis. Journal of the American Chemical Society, 136(35), 12624–12630. https://doi.org/10.1021/ja505134w
17. Sutton, P., Saunier, J., Mason, K. A., Pearcy, A. C., Lao, K. U., & El-Shall, M. S. (2024). Formation of complex organics by covalent and non-covalent interactions of the sequential reactions of 1–4 acrylonitrile molecules with the benzonitrile radical cation. Physical Chemistry Chemical Physics, 26(6), 29708–29717. https://doi.org/10.1039/D3CP05023A
18. Koo, T. Y., Lai, H., Nomura, D. K., et al. (2023). N-Acryloylindole-alkyne (NAIA) enables imaging and profiling new ligandable cysteines and oxidized thiols by chemoproteomics. Nature Communications, 14, 3564. https://doi.org/10.1038/s41467-023-39268-w
19. Deeks, E. D. (2017). Neratinib: First global approval. Drugs, 77(15), 1695–1704. https://doi.org/10.1007/s40265-017-0811-4
20. Chounta, V., et al. (2021). Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8 weeks (ATLAS-2M). Patient. https://doi.org/10.1007/s40271-021-00524-0
21. Sissouma, D., Ouattara, M., Koné, M., Menan, H., Adjou, A., & Ouattara, L. (2011). Synthesis and in vitro nematicidal activity of new chalcones vectorized by imidazopyridine. African Journal of Pharmacy and Pharmacology, 5(18), 2086–2093.
22. Kovalenko, N. V., Kutrov, G. P., Filipchuk, Y. V., & Kornilov, M. Y. (2002). Reaction of 1,3-dibromo- and 1,3-dichloroacetone with 2-aminoazaheterocycles. Chemistry of Heterocyclic Compounds, 38(5), 590–597.
23. Endoori, S., Gulipalli, K. C., Bodige, S., Chandra, J. N. N. S., & Seelam, N. (2020). Design, synthesis, anti-cancer activity, and in silico studies of novel imidazo[1,2-a]pyridine derivatives. Russian Journal of General Chemistry, 90(9), 1727–1736.
24. Kutrov, G. P., Kovalenko, N. V., & Volovenko, Y. M. (2008). Synthesis and properties of cyanomethyl derivatives of imidazo[1,2-a]pyridine, imidazo[1,2-a]pyrimidine, and imidazo[2,1-b]thiazole. Russian Journal of Organic Chemistry, 44(2), 257–262. https://doi.org/10.1134/S1070428008020144
25. Claridge, T. D. W. (2016). High Resolution NMR Techniques in Organic Chemistry (3rd ed.). Amsterdam: Elsevier. https://doi.org/10.1016/C2014-0-03860-7